Barbara Debaveye

Intermediate-dose versus low-dose low-molecular-weight heparin in pregnant and post-partum women with a history of venous thromboembolism (Highlow study): an open-label, multicentre, randomised, controlled trial

Ingrid M. Bistervels, Andréa Buchmuller, Hanke M.G. Wiegers, Fionnuala Ní Áinle et autres

nl, fr, ie, be, no, dk, ca, us, ru (code pays fourni par la source)

Modulation of thromboinflammation in hospitalized COVID‐19 patients with aprotinin, low molecular weight heparin, and anakinra: The DAWn‐Antico study

Matthias M. Engelen, Quentin Van Thillo, Albrecht Betrains, Iwein Gyselinck et autres

Background Thromboinflammation plays a central role in severe COVID‐19. The kallikrein pathway activates both inflammatory pathways and contact‐mediated coagulation. We investigated if modulation of the thromboinflammatory response improves outcomes in hospitalized COVID‐19 patients. Methods Inmulticenter open‐label randomized clinical trial (EudraCT 2020‐001739‐28), patients …

be (code pays fourni par la source)

Corrigendum to “itraconazole for COVID-19: Preclinical studies and a proof-of-concept randomized clinical trial Laurens”

Laurens Liesenborghs, Isabel Spriet, Dirk Jochmans, Ann Belmans et autres

This project has received funding from the Covid-19-Fund KU Leuven / University Hospitals Leuven, the COVID-19 call of the Research Foundation -\nFlanders (FWO) (grant G0G4820N), the European Union’s Horizon 2020 research and innovation program (Grant 101,003,627, Swift COronavirus\ntherapeutics REsponse project) and the …

be (code pays fourni par la source)

Itraconazole for COVID-19: preclinical studies and a proof-of-concept randomized clinical trial

Laurens Liesenborghs, Isabel Spriet, Dirk Jochmans, Ann Belmans et autres

BACKGROUND: The antifungal drug itraconazole exerts in vitro activity against SARS-CoV-2 in Vero and human Caco-2 cells. Preclinical and clinical studies are required to investigate if itraconazole is effective for the treatment and/or prevention of COVID-19. METHODS: Due to the initial absence …

be (code pays fourni par la source)

A randomized, open-label, adaptive, proof-of-concept clinical trial of modulation of host thromboinflammatory response in patients with COVID-19: the DAWn-Antico study

Thomas Vanassche, Matthias M. Engelen, Quentin Van Thillo, Joost Wauters et autres

BACKGROUND: The peak of the global COVID-19 pandemic has not yet been reached, and many countries face the prospect of a second wave of infections before effective vaccinations will be available. After an initial phase of viral replication, some patients develop a …

be, us (code pays fourni par la source)

Itraconazole for COVID-19: Preclinical Studies and a Proof-of-Concept Pilot Clinical Study

Laurens Liesenborghs, Isabel Spriet, Dirk Jochmans, Ann Belmans et autres

be, nz, au (code pays fourni par la source)

Abnormal uterine bleeding in VTE patients treated with rivaroxaban compared to vitamin K antagonists

Nico De Crem, Kathelijne Peerlinck, Thomas Vanassche, Kristine Vanheule et autres

be, nl (code pays fourni par la source)